Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Yuji Shiba's Biography

Yuji Shiba, Professor, Department of Regenerative Science and Medicine, Shinshu University

Dr. Shiba is currently a Professor of Regenerative Science and Medicine, Cardiovascular Medicine at Shinshu University. After he obtained his MD from Shinshu University in 1998, he worked as a physician/cardiologist until he started his research training. He received his PhD in 2007 from Shinshu University and moved to the University of Washington (Mike Laflamme Lab) for post-doctoral training, where he started stem cell research. He moved back to Japan in 2011 and established his new lab.

Dr. Shiba is broadly interested in the use of stem cells for cardiac repair, but particularly emphasis on:

1) Electrophysiological consequences following the transplantation of stem cell-derived cardiomyocytes
2) Preclinical transplantation studies with non-human primates

Yuji Shiba Image

Preclinical Transplantation Study of iPS Cell-Derived Cardiomyocytes in Non-Human Primate

Monday, 11 November 2019 at 13:30

Add to Calendar ▼2019-11-11 13:30:002019-11-11 14:30:00Europe/LondonPreclinical Transplantation Study of iPS Cell-Derived Cardiomyocytes in Non-Human PrimateCell and Gene Therapy Asia 2019 in Kobe, JapanKobe,

Induced pluripotent stem cells (iPSCs) have promising potential as a source of autologous patient-specific cardiomyocytes for cardiac repair, obviously providing a major benefit in terms of immune rejection. However, autologous transplantation comes with substantial challenges related to manufacturing and regulation. Although major histocompatibility complex (MHC)-matched allogeneic transplantation is a promising alternative strategy, surprisingly few immunological studies have been carried out with iPSCs. Here, we established an allogeneic transplantation model using cynomolgus monkey, whose MHC structure is identical to that of humans. iPSCs were generated from fibroblasts from an animal with a homozygous MHC haplotype (HT4), and the cells were differentiated into cardiomyocytes (iPSC-CMs). Five HT4 heterozygous monkeys were subjected to myocardial infarction followed by direct intramyocardial injection of the iPSC-CMs. The grafted cardiomyocytes survived for 12 weeks with no evidence of immune rejection under treatment of clinically relevant doses of methylprednisolone and tacrolimus, and they showed indisputable electrical integration with host cardiomyocytes as assessed by use of our novel fluorescent calcium indicator, G-CaMP7.09. In addition, transplantation of the iPSC-CMs improved cardiac contractile function at 4 and 12 weeks post transplantation; however, the incidence of ventricular tachycardia was transiently but significantly increased when compared to the vehicle-treated control. MHC-matched allogeneic transplantation of iPSC-CMs regenerates infarcted non-human primate heart. Further research to control post-transplant arrhythmias is warranted.

Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe,